Empagliflozin inhibits cardiac hypertrophy via a mechanism involving integrin signalling.
BACKGROUND AND PURPOSE Pathological cardiac hypertrophy precipitates heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, confers cardiovascular protection beyond glycaemic control, but the molecular basis of its direct anti-hypertrophic action remains undefined. EXPERIMENTAL APPRO...